Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

NCT02220894 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1274

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: pembrolizumab
DRUG: carboplatin
DRUG: paclitaxel
DRUG: pemetrexed

Sponsor

Merck Sharp & Dohme LLC